The HLA-B7 model was generated by Pharmexa-Epimmune. The model was created by microinjecting a chimeric transgene combining a fragment of the cDNA clone of the human HLA-B*0702 gene that included leader sequence, α1 and α2 domains ligated to a fragment of the murine H2-Kb gene containing the α3, transmembrane and cytoplasmic domains, all under the control of the murine H2-Kb promoter. This transgene was microinjected into CxB6 zygotes. The resultant mice from Founder Line B7.xx were on backcrossed four generations to C57BL/6J. They were then crossed onto murine B2m knockout/human B2m microinjected line from Chella David at Mayo. This crossbred line was backcrossed two additional generations to C57BL/6J and then bred to homozygosity for all three genes. Taconic received stock from Pharmexa-Epimmune in 2008. The line was embryo transfer derived. SNP testing showed that the line was not congenic, and so additional backcrosses were initiated. The line was then intracrossed to homozygosity for all three genes. In the production colony, wild type BALB/cAnNTac females are bred to triple homozygous males on the B6 background to produce CB6F1 pups.
Alexander J, Oseroff C, Sidney J, Sette A. (2003) Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes. Human Immunology 64:211-223.
Koller BH, Smithies O. (1989) Inactivating the beta 2-microglobulin locus in mouse embryonic stem cells by homologous recombination. Proc Natl Acad Sci USA 86:8932-8935.
Krimpenfort P, Rudenko G, Hochstenbach F, Guessow D, Berns A, Ploegh H. (1987) Crosses of two independently derived transgenic mice demonstrate functional complementation of the genes encoding heavy (HLA-B27) and light (beta 2-microglobulin) chains of HLA class I antigens. EMBO J, 1987, 6(6):1673-1676.
Welcome! Tell us a little about yourself